Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

Article  PubMed  Google Scholar 

Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57. https://doi.org/10.1016/S0140-6736(18)32557-1.

Article  PubMed  Google Scholar 

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20. https://doi.org/10.1056/NEJMoa055531.

Article  CAS  PubMed  Google Scholar 

Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21. https://doi.org/10.1200/JCO.2010.33.0597.

Article  CAS  PubMed  Google Scholar 

Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20. https://doi.org/10.1056/NEJMoa072252.

Article  CAS  PubMed  Google Scholar 

Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93. https://doi.org/10.1200/JCO.2011.36.5908.

Article  CAS  PubMed  Google Scholar 

Bang Y-J, Kim Y-W, Yang H-K, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (Classic): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21. https://doi.org/10.1016/S0140-6736(11)61873-4.

Article  CAS  PubMed  Google Scholar 

Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol. 2019;37:1296–304. https://doi.org/10.1200/JCO.18.01138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang Y-K, Yook JH, Park Y-K, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39:2903–13. https://doi.org/10.1200/JCO.20.02914.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang X, Liang H, Li Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22:1081–92. https://doi.org/10.1016/S1470-2045(21)00297-7.

Article  CAS  PubMed  Google Scholar 

Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653–60. https://doi.org/10.1002/bjs.9484.

Article  CAS  PubMed  Google Scholar 

Iwasaki Y, Sasako M, Yamamoto S, et al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol. 2013;107:741–5. https://doi.org/10.1002/jso.23301.

Article  CAS  PubMed  Google Scholar 

Terashima M, Iwasaki Y, Mizusawa J, et al. Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer. 2019;22:1044–52. https://doi.org/10.1007/s10120-019-00941-z.

Article  CAS  PubMed  Google Scholar 

Iwasaki Y, Terashima M, Mizusawa J, et al. Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer. 2021;24:492–502. https://doi.org/10.1007/s10120-020-01136-7.

Article  CAS  PubMed  Google Scholar 

Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419–30. https://doi.org/10.1056/NEJMoa2004413.

Article  CAS  PubMed  Google Scholar 

Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97. https://doi.org/10.1016/S0140-6736(10)61121-X.

Article  CAS  PubMed  Google Scholar 

Japanese Gastric Cancer A. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1–25. https://doi.org/10.1007/s10120-022-01331-8

Kataoka K, Tokunaga M, Mizusawa J, et al. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study). Jpn J Clin Oncol. 2015;45:1082–6. https://doi.org/10.1093/jjco/hyv134.

Article  PubMed  Google Scholar 

Bartley AN, Washington MK, Colasacco C, et al. HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35:446–64. https://doi.org/10.1200/JCO.2016.69.4836.

Article  CAS  PubMed  Google Scholar 

Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: Results from a validation study. Histopathology. 2008;52:797–805. https://doi.org/10.1111/j.1365-2559.2008.03028.x.

Article  CAS  PubMed  Google Scholar 

Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011; 14: 113–23. https://doi.org/10.1007/s10120-011-0042-4.

Katayama H, Kurokawa Y, Nakamura K, et al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016;46:668–85. https://doi.org/10.1007/s00595-015-1236-x.

Article  PubMed  Google Scholar 

Hofheinz RD, Merx K, Haag GM, et al. FLOT versus FLOT/trastuzumab/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group. J Clin Oncol. 2022;40:3750–61. https://doi.org/10.1200/JCO.22.00380.

Article  CAS  PubMed  Google Scholar 

Wagner AD, Grabsch HI, Mauer M, et al. EORTC-1203-GITCG—the “INNOVATION”-trial: effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer. 2019;19:494. https://doi.org/10.1186/s12885-019-5675-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sato Y, Kurokawa Y, Doki Y, et al. A phase II study of preoperative chemotherapy with docetaxel, oxaliplatin and S-1 in gastric cancer with extensive lymph node metastasis (JCOG1704). Future Oncol. 2020;16:31–8. https://doi.org/10.2217/fon-2019-0528.

Article  CAS  PubMed  Google Scholar 

Kita R, Yanagimoto Y, Imazeki H, et al. Protocol digest of a randomized controlled adaptive phase II/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma: Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG). Jpn J Clin Oncol. 2023. https://doi.org/10.1093/jjco/hyad149.

Article  PubMed  PubMed Central  Google Scholar 

Sengupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK. Trastuzumab-induced cardiotoxicity: Heart failure at the crossroads. Mayo Clin Proc. 2008;83:197–203. https://doi.org/10.4065/83.2.197.

Article  CAS  PubMed  Google Scholar 

Lenz H-J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12:601–9. https://doi.org/10.1634/theoncologist.12-5-601.

Article  CAS  PubMed  Google Scholar 

Ito S, Sano T, Mizusawa J, et al. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 2017;20:322–31. https://doi.org/10.1007/s10120-016-0619-z.

Article  CAS  PubMed  Google Scholar 

Shao Z, Pang D, Yang H, et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY Phase 3 randomized clinical trial. JAMA Oncol. 2020;6: e193692. https://doi.org/10.1001/jamaoncol.2019.3692.

Article  PubMed  Google Scholar 

Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32. https://doi.org/10.1016/S1470-2045(11)70336-9.

Article  CAS  PubMed  Google Scholar 

Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377–84. https://doi.org/10.1016/S0140-6736(09)61964-4.

Article  CAS  PubMed  Google Scholar